Evidence map›Paper›PMID 31640639›Full record

ArticleBMC public health2019

Mass screening for hepatitis B and C in Southern Upper Egypt.

Gamal Soliman, Mahmoud S Elzalabany, Tarek Hassanein, F DeWolfe Miller

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Gamal SolimanTropical Medicine, Gastroenterology and Hepatology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mahmoud S ElzalabanyInternal Medicine Department, Ahmed Maher Teaching Hospital, Cairo, Egypt.
Tarek HassaneinSouthern California Liver Centers, Coronado, CA, USA.
F DeWolfe MillerJohn A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA. dewolfe@hawaii.edu.ORCID http://orcid.org/0000-0002-5130-056X
Al-Azhar University · EGResearch Institute of Ophthalmology · EGSouthern California Reproductive Center · USUniversity of Hawaiʻi at Mānoa · US

Funding

Tahya Misr Egyptian National Fund NA
6 · The paper itself

Abstract

backgroundIt is well documented that Egypt has the highest prevalence of hepatitis C virus (HCV) infection in the world. The recent development of highly effective direct acting antiviral drugs (DAAs), has opened the possibility of treating and curing HCV infection in the Egyptian population on a large scale.

methodsA screening demonstration project was implemented in southern Egypt in and around the city of Luxor. Free screening and if indicated, treatment, was offered to those 16 years or older for anti-HCV antibodies (anti-HCV) and hepatitis B surface antigen (HBsAg) using third generation enzyme immunoassays (Enzygnost® Anti-HCV and HbsAg). Statistical methods included estimation of odds ratios (OR) and 95% confidence intervals (95% CI).

resultsThere was a large turnout of 67,042 persons who were screened in a 12-month period starting in June 2016. Thirty-one thousand nine hundred sixty-four males (47.7%) and 35,074 females (52.3%) were screened with a mean age of 43.6 ± 14.3 years. Nine thousand seven hundred one patients (14.5%) were positive for anti-HCV and 2950 (4.4%) for HBsAg. Prevalence of anti-HCV was significantly higher in males than females (19.67% vs.9.73% OR = 2.27; CI 2.2 to 2.4; p < 0.001) and the same for HBsAg (6.2% vs. 2.8% OR = 2.3; CI 2.2 to 2.5; p < 0.001). The prevalence of anti-HCV was significantly associated with age (p < 0.001), ranging from between 1 and 4% in individuals below the age of 40 years, then increased steadily to 42% at age 60 followed by a precipitous decline in age specific prevalence.

conclusionsThe results showed unanticipated patterns in the Luxor area of anti-HCV and HBsAg by age and gender in contrast to previous reports on this unique HCV epidemic in Egypt. Moreover, the level and rate of turnout, cost, and other logistical issues, provided essential information for effective planning, design, and evaluation methods for larger national mass screening and treatment programs.

Indexed as

AdolescentAdultCommunity Health ServicesEgyptFemaleHepacivirusHepatitis BHepatitis B Surface AntigensHepatitis CHepatitis C AntibodiesHumansMaleMass ScreeningMiddle AgedPrevalenceSeroepidemiologic StudiesHepatitis B Surface AntigensHepatitis C AntibodiesEgyptEpidemiologyHepatitis B virusHepatitis C virusMass screening

Identifiers

PMID31640639
PMCPMC6805514
OpenAlexW2982029575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.